Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2

Conditions

Neoplasms 6Pain 3Burns 2Breakthrough Pain 2Anemia, Sickle Cell 2Agnosia 2Pain, Postoperative 1Pain, Intractable 1Lung Neoplasms 1Intrathecal Dexmedetomidine 1Dyspnea, Paroxysmal 1Colonic Neoplasms 1Cancer Pain 1Breast Neoplasms 1Bone Metastases 1

Interventions

Cyclophosphamide 3fludarabine phosphate 2Whole-Body Irradiation 2Fentanyl 2thymoglobulin 1fludarabine 1Thiotepa 1Tacrolimus 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Melphalan 1Medical Marijuana 1Dexamethasone 1Busulfan 1Bortezomib 1Antilymphocyte Serum 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Anemia, Sickle Cell × Fentanyl × Clear all
NCT00236041 2014-05-09

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
38 enrolled
Classical hematology

Agnosia, Anemia, Sickle Cell, Burns, Neoplasms, Breakthrough Pain

NCT00236093 2014-05-09

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
Classical hematology

Anemia, Sickle Cell, Burns, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡